Experimental drug aims to tame severe COVID-19 inflammation
NCT ID NCT04483973
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests an experimental drug called SPI-1005 (ebselen) in adults hospitalized with severe COVID-19. Participants receive either the drug or a placebo to see if the drug is safe and helps improve recovery. The trial is randomized and double-blind, meaning neither patients nor doctors know who gets the real drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ebselen (SPI-1005)
What this could lead to
If it works, this could point toward a new treatment option for severe COVID-19 that reduces inflammation and speeds recovery.
What could go wrong
This is a small, early-phase trial, so results may not apply broadly. The drug may cause side effects or prove no better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University
Durham, North Carolina, 27710, United States
-
Kansas University Medical Center
Kansas City, Kansas, 66160, United States
-
St. Luke's Cystic Fibrosis Center of Idaho
Boise, Idaho, 83702, United States
-
University of Texas Southwestern
Dallas, Texas, 75390, United States
-
Wake Forest University
Winston-Salem, North Carolina, 27109, United States
-
Washington University in St. Louis
St Louis, Missouri, 63130, United States
-
Yale University
New Haven, Connecticut, 96510, United States